Supply of Sustanon 250 Injection ampoule by Merck Sharp & Dohme Australia Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the supply of therapeutic goods in Australia, ensuring their quality, safety, and efficacy. This Act was introduced to address the need for a comprehensive legal framework governing the therapeutic goods industry, thereby protecting public health and ensuring consumer safety. The Therapeutic Goods Act 1989 is overseen by the Australian Parliament and its primary policy objective is to safeguard the health of the Australian public by regulating the quality, efficacy, and safety of therapeutic goods. On January 24, 2013, the delegate of the Secretary of the Department of Health and Ageing granted consent for the supply of Sustanon 250 Injection ampoule, produced by Merck Sharp & Dohme Australia Pty Ltd, under specific conditions. This consent pertains to the use of outdated sponsor details on the product's labels, with the aim of maintaining the product's current quality and safety standards while addressing compliance issues.

Scope and Application

The Therapeutic Goods Act 1989, as referenced in the Gazette entry C2013G00648, applies to the regulation and control of therapeutic goods within Australia. Specifically, section 14 and 14A of the Act relate to the approval and consent required for the supply of therapeutic goods. In this instance, the Act applies to the supply of the specific product Sustanon 250 Injection ampoule, which is being supplied by Merck Sharp & Dohme Australia Pty Ltd. The consent granted by the delegate of the Secretary of the Department of Health and Ageing pertains to batches 163218 and 247049 of this product, under the condition that the labels used are identical to those previously employed, bearing the details of the former sponsor, Schering-Plough. The consent is subject to the requirement that no other changes are made to the product and that arrangements are in place to handle any complaints or queries regarding the product. The jurisdictional reach of the Act is national, governing the therapeutic goods industry across Australia.

Key Provisions

Under the Therapeutic Goods Act 1989, the delegate of the Secretary of the Department of Health and Ageing granted consent for Merck Sharp & Dohme Australia Pty Ltd to supply batches 163218 and 247049 of the product Sustanon 250 Injection ampoule (section 14 and 14A). This consent is subject to specific conditions, as outlined in the notice. The primary condition is that the product labels must remain identical to those currently in use, which include the details of the previous sponsor, Schering-Plough, instead of the current sponsor, Merck Sharp & Dohme Australia Pty Ltd (section 14(2)(a)). Additionally, no other changes have been made to the product itself (section 14(2)(b)), and arrangements are to be made to ensure that any complaints or queries regarding the product are addressed promptly (section 14(2)(c)). The obligations imposed by the Act on the parties involved are quite clear. The company must ensure that the product labels do not change and that any customer complaints or queries are managed efficiently. The Therapeutic Goods Administration will likely monitor the company's compliance with these conditions, including verifying that the labels and the product itself remain unchanged and that the complaint handling arrangements are effective. Breach of the conditions outlined in the notice could lead to various consequences. While the notice does not explicitly state the penalties for non-compliance, under the Therapeutic Goods Act 1989, offences can result in substantial fines and, in severe cases, imprisonment. For instance, supplying therapeutic goods that do not comply with the regulations can incur fines of up to $1.1 million for a corporation and imprisonment for up to five years (section 32ZD). Additionally, the Therapeutic Goods Administration may take enforcement actions, such as recalls or further restrictions on the supply of the product, to ensure public safety and compliance with the legislation.